Volume 15, Number 7—July 2009
Dispatch
Lack of Macrolide Resistance in Chlamydia trachomatis after Mass Azithromycin Distributions for Trachoma
Kevin Cyrus Hong, Julius Schachter, Jeanne Moncada, Zhaoxia Zhou, Jenafir House, and Thomas M. Lietman
Table
Antimicrobial drug susceptibilities of Chlamydia trachomatis, Ethiopia*
| Treatment status | Serotype | Azithromycin† |
Doxycycline† |
|||
|---|---|---|---|---|---|---|
| MIC | MCC | MIC | MCC | |||
| 4 biannual | A/Har13 | 0.5 | 0.5 | 0.03 | 0.03 | |
| Ba/Apache-2 | 0.5 | 0.5 | 0.03 | 0.03 | ||
| Ba/Apache-2 | 0.5 | 0.5 | 0.03 | 0.06 | ||
| Ba/Apache-2 | 0.25 | 0.5 | 0.03 | 0.06 | ||
| Ba/Apache-2 | 0.5 | 0.5 | 0.03 | 0.06 | ||
| Ba/Apache-2 |
0.5 |
0.5 |
0.03 |
0.03 |
||
| None | A/Har 13 | 0.5 | 0.5 | 0.03 | 0.03 | |
| A/Har 13 | 0.5 | 0.5 | 0.03 | 0.03 | ||
| A/Har 13 | 0.5 | 1 | 0.015 | 0.06 | ||
| Ba/Apache-2 | 0.25 | 0.25 | 0.03 | 0.03 | ||
*Samples taken in 2006, 18 months after 4 biannual treatments in 2003–2004. MCC, minimum chlamydicidal concentration.
†MIC and MCC values given in μg/mL.
